 |
It is the goal of our staff to provide you with the latest
women's healthcare innovations to address infertility and
coexisting gynecologic problems. Backed by a superb laboratory
team, CRH has enabled thousands of couples to conceive.
Contact us to schedule
an appointment or have additional questions about infertility
treatment at CRH. |
| |
|
|
"Irreversible Tubal Sterilization..."
 |
In 1996, more than two million tubal
sterilizations were performed in the U.S., for an average
annual rate of 1.5 per 1,000 women. The success of sterilization
reversal depends on the type of procedure originally performed,
the patient's age, and whether there are other infertility
factors present. In ideal circumstances, 50-75 percent of the
women who have sterilization reversal surgery may be able to
conceive. Another option, which avoids surgery, is oocyte (egg)
aspiration, in vitro fertilization and embryo transfer (IVF-ET).
In this report we describe the case of a woman
who had a previous tubal cauterization, a previous right
oophorectomy, diminished ovarian reserve and luteal phase
deficiency. Her husband had asthenozoospermia and
teratozoospermia.
|


|
Twins Sarah and Clayton were born after
successful in vitro fertilization at CRH. They are examples of
the thousands of successful outcomes in our fertility programs
including IVF. |
 |
IVF resulting in Twin Delivery
Following Irreversible Tubal Sterilization
Case Report
Mrs. Peggy Schultz is a 35-year-old woman (Gravida 2,
Para 2) with a six-year history of secondary infertility and a
previous tubal sterilization. A previous hysterosalpingogram had
shown bilateral tubal occlusion and a normal endometrial cavity. Her
day 3 FSH was 5.9 miu/ml, with an E2 level of 62 pg/ml.
Her husband's semen analysis demonstrated a motility of 8% and a
normal morphology of 9%. Peggy had documentation of granulosa
cell programmed cell death (apoptosis) related to her chronological
age and poor oocyte quality. Thus, she requested proceeding with IVF-ET
rather than a tubal microanastomosis.
“Eight cell embryos were replaced into the
endometrial cavity followed by hormone supplementation to correct
luteal phase deficiency.”
Controlled supra-ovulation was attained with
follicular phase leuprolide acetate (Lupron; TAP Pharmaceuticals,
North Chicago, IL), followed by 10 days of gonadotropin
administration (daily dose: 300 miu FSH; Repronex, Ferring
Pharmaceuticals Inc., White Plains, NJ). With multiple follicles of
18 mm, and an E2 level of 9,765 pg/ml, 10,000
iu HCG (Novarel™,
Ferring Pharmaceuticals Inc., White Plains, NJ) then was given
intramuscularly to trigger resumption of the meiotic prophase in
preparation for oocyte aspiration.
Twenty
oocytes were retrieved 36 hours after HCG administration, and after
conventional insemination, 15 became normally fertilized. Gametes
were prepared in human tubal fluid (HTF) supplemented with 10% human
serum albumin (HSA; In Vitro Care, San Diego, CA), and for culture
to day 3, all zygotes were placed into IVC-1 plus 10% HSA (In Vitro
Care). On day 3 of development, seven of the embryos were of good
quality, possessing eight cells.
On day 3 after retrieval, the patient was
asymptomatic and presented for ET. At transfer, four
eight-cell pre-embryos were replaced into the endometrial cavity.
This transfer resulted in a viable dizygotic twin
pregnancy that experienced no obstetrical complications. The twins
were delivered vaginally at 351/2 weeks’ gestation. Baby
Sarah Schultz weighed 5’ 1” and measured 18”. Twin Clayton Schultz
weighed 5’ 10” and measured 171/2” at birth. Sarah and
Clayton currently are developing normally at 16 months.
Discussion
The
increasing success of IVF allows for alternative therapeutic options
to tubal reversals. The results with IVF in terms of live births,
too, have equaled and, in many cases, improved upon the results from
tubal anastomosis. (Ironically, the initial indication for using IVF
in humans was irreversible damage to or destruction of the fallopian
tubes.)
Fewer tubal ligation reversals are being performed
because of the increasing success of and access to IVF procedures.
There have been no trials directly comparing these two treatments.
Furthermore, no comparisons of the relative cost-effectiveness of
the two approaches have been published. Anecdotally, patients who
desire at most one more pregnancy opt for IVF because further birth
control methods would not be needed if they successfully conceived
and delivered from an IVF cycle.
“The
increasing success of IVF allows for alternative therapeutic options
to tubal reversals”
There are a number of factors that may help decide
whether fallopian tube anastomosis or IVF is the best approach. One
key question is whether the patient will need additional treatment
to conceive after fertility surgery. Once the cost of this treatment
is taken into consideration, the more cost-effective option may be
advantageous. Thus, polycystic ovarian syndrome is likely to require
ovulation induction treatment, whether the patient chooses surgery
or IVF. In these cases IVF may be a more cost-effective treatment.
Also, if the husband's semen analysis is dismal, IVF is usually a
better option, as ICSI can provide excellent results when the man
has fertility problems.
Tubal anastomosis poses a risk of ectopic pregnancy;
the risk with IVF is less than 3%. IVF requires multiple office
visits, but a surgical incision is avoided and recovery is in hours
rather than days or weeks. The cost of each procedure varies widely
from institution to institution, but is in comparable ranges.
Pregnancy rates after surgical correction depend on
the patient’s age, the partner's fertility status, the type of prior
tubal ligation, the site on the tube of the sterilization, the
health of the tubes (free of infection or scarring), the surgeon's
microsurgical skills and experience, and tubal length after
correction.
Conclusions
IVF –ET is an effective and non-surgical
treatment alternative for women after tubal ligation.
In spite of this couple’s irreversible
tubal sterilization, poor oocyte quality, previous oophorectomy and
a sperm factor, a successful outcome is demonstrated by a twin
delivery following IVF-ET.
IVF-ET must be considered a
complementary rather than a competitive procedure. Adequate patient
selection is crucial to find the best therapeutic approach
To make an
appointment, please call us TODAY at
615-321-8899.
|
About CRH |
Causes of Infertility | Treatments
| Corrective Surgery |
Facilities | Success Rates
Egg Donation |
Embryo Adoption | Testimonials
| Financial Services | Glossary |
Contact Us
| Home
The Center for Reproductive Health | 2008 | All Rights Reserved
|